Women who are recently diagnosed with advanced-stage epithelial ovarian cancer can be treated well with Platinum-based neoadjuvant chemotherapy followed by delayed primary surgery. Here we have described RECIST and Gynecologic Cancer InterGroup (GCIG) CA125 responding differently in patients receiving platinum-based neoadjuvant chemotherapy, which is followed by DPS in the ICON8 trial.
June 6, 2011, and Nov 28, 2014, 1566 women were enrolled in ICON8, of whom 779 (50%) were planned for neoadjuvant chemotherapy followed by DPS. Of 564 women who had RECIST-evaluable disease at trial entry, 348 (62%) had a complete or partial response. Median progression-free survival was 14·4 months (95% CI 9·2–28·0; 297 events) for patients with a RECIST complete or partial response and 13·3 months (8·1–20·1; 171 events) for those with RECIST stable disease. Complete cytoreduction was achieved in 290 (50%) of 576 women with a GCIG CA125 response and 30 (30%) of 101 women without a GCIG CA125 response.
Both the RECIST and GCIG CA125 responses are very much restarted to individuals. If you are not a good expression of these, then things can get opposite. This never means that you cannot opt for surgery. One needs to be very sure that ill expression or no expression of both or one of these never means you will be clinically restricted for the surgery.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30591-X/fulltext
